
Ausperbio Presents Interim Phase Iib AHB-137 Clinical Data In A Late-Breaking Abstract At EASLTM Congress 2025
(MENAFN- PR Newswire) SAN FRANCISCO, May 7, 2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio ), a clinical-stage biotechnology company, today announced the presentation of end-of-treatment (EOT) …